Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) that causes the steady-state activation of extracellular signal-regulated kinase (ERK). We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors...

詳細記述

保存先:
書誌詳細
主要な著者: Tap, William D, Gong, Ke-Wei, Dering, Judy, Tseng, Yiou, Ginther, Charles, Pauletti, Giovanni, Glaspy, John A, Essner, Richard, Bollag, Gideon, Hirth, Peter, Zhang, Chao, Slamon, Dennis J
フォーマット: Artigo
言語:Inglês
出版事項: Neoplasia Press Inc. 2010
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2915408/
https://ncbi.nlm.nih.gov/pubmed/20689758
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料